CO5650228A2 - Sales farmaceuticamente utiles de derivados de acido carboxilico - Google Patents

Sales farmaceuticamente utiles de derivados de acido carboxilico

Info

Publication number
CO5650228A2
CO5650228A2 CO05129035A CO05129035A CO5650228A2 CO 5650228 A2 CO5650228 A2 CO 5650228A2 CO 05129035 A CO05129035 A CO 05129035A CO 05129035 A CO05129035 A CO 05129035A CO 5650228 A2 CO5650228 A2 CO 5650228A2
Authority
CO
Colombia
Prior art keywords
salt
phenylethyl
ethoxy
hexyl
amino
Prior art date
Application number
CO05129035A
Other languages
English (en)
Inventor
Carl Johan Aurell
Mikael Dahlstrom
Alstermark Eva-Lotte Lindstedt
Anna Minidis
Bengt Ohlsson
Erica Stahle
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CO5650228A2 publication Critical patent/CO5650228A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
    • C07C235/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

1.- Un compuesto seleccionado de una o más de las siguientes: una sal de (1R,2S)-2-hidroxiindan-1-amina de ácido (2S)-2-etoxi-3-(4-{2-[hexil(2-feniletil)amino]-2-oxoetoxi}fenil)propanoico; una sal de L-arginina de ácido (2S)-2-etoxi-3-(4-{2-[hexil(2-feniletil)amino-2-oxoetoxifenil)propanoico; una sal de terc-butilamina de ácido (2S)-2-etoxi-3-(4-{2-[hexil(2-feniletil)amino-2-oxoetoxifenil)propanoico; una sal de colina de ácido (2S)-2-etoxi-3(4- {2- [hexil(2- feniletil)amino]- 2 -oxoetoxi}fenil) propanoico; una sal de adamantilamina de ácido (2S)-2-etoxi- 3 -(4{2- [hexil(2- feniletil)amino]- 2 -oxoetoxi}fenil) propanoico; una sal de N-bencil-2-feniletanaminio de ácido (2S)-2-etoxi-3-(4-{2-[hexil(2-feniletil)amino]-2-oxoetoxi}fenil)propanoico; una sal de N-bencil-2-(bencilamino) etanaminio de ácido (2S)-2-etoxi-3-(4-{2-[hexil(2-feniletil)amino]-2-oxoetoxi}fenil)propanoico; o una sal de tris(hidroximetil)metilamina de ácido (2S)-2-etoxi-3- (4-{2 -[hexil (2-feniletil)amino ]-2 -oxoetoxi} fenil)propanoico.3.- Un compuesto de acuerdo con la reivindicación 1, en donde el compuesto se selecciona de:una sal de adamantilamina de ácido (2S)-2-etoxi-3-( 4-{2-[hexil(2-feniletil) amino]-2-oxoetoxi} fenil)propanoico;una sal de N-bencil-2-feniletanaminio de ácido (2S)-2-etoxi-3-(4-{2-[hexil(2-feniletil)amino ]-2-oxoetoxi} fenil)propanoico; o una sal de N-bencil-2-(bencilamino)etanaminio de ácido (2S)-2-etoxi-3-(4-{2-[hexil(2-feniletil)amino]- 2-oxoetoxi} fenil)propanoico.4.- Un compuesto seleccionado de:una sal de (1R,2S)-2-hidroxiindan-1-amina de ácido (2S)-2-etoxi- 3 -(4- {2[hexil(2- feniletil)amino]- 2 -oxoetoxi}fenil) propanoico;una sal de L-arginina de ácido (2S)-2-etoxi-3-(4-{2-[hexil(2-feniletil )amino- 2- oxoetoxifenil )propanoico; o una sal de terc-butilamina de ácido (2S)-2-etoxi-3-( 4-{2-[hexil(2-feniletil) amino- 2-oxoetoxifenil )propanoico.5.- Una sal como se reivindica en una cualquiera de las reivindicaciones 1 a 4, que puede ser un solvato, un hidrato, un solvato/hidrato mixto, un solvato o un anhidrato.6.- Una sal como se reivindica en una cualquiera de las reivindicaciones 1 a 5 en forma cristalina o parcialmente cristalina.
CO05129035A 2003-06-18 2005-12-22 Sales farmaceuticamente utiles de derivados de acido carboxilico CO5650228A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0314129.8A GB0314129D0 (en) 2003-06-18 2003-06-18 Therapeutic agents

Publications (1)

Publication Number Publication Date
CO5650228A2 true CO5650228A2 (es) 2006-06-30

Family

ID=27636788

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05129035A CO5650228A2 (es) 2003-06-18 2005-12-22 Sales farmaceuticamente utiles de derivados de acido carboxilico

Country Status (23)

Country Link
US (1) US20060142389A1 (es)
EP (1) EP1638922A1 (es)
JP (1) JP3822900B1 (es)
KR (1) KR20060027348A (es)
CN (1) CN1809529A (es)
AR (1) AR044801A1 (es)
AU (1) AU2004247610B2 (es)
BR (1) BRPI0411525A (es)
CA (1) CA2528932A1 (es)
CO (1) CO5650228A2 (es)
GB (1) GB0314129D0 (es)
IL (1) IL172167A0 (es)
IS (1) IS8231A (es)
MX (1) MXPA05013714A (es)
MY (1) MY137277A (es)
NO (1) NO20055922L (es)
RU (1) RU2005138590A (es)
SA (1) SA04250169B1 (es)
TW (1) TW200503677A (es)
UA (1) UA81807C2 (es)
UY (1) UY28375A1 (es)
WO (1) WO2004110984A1 (es)
ZA (1) ZA200510252B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0314079D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
SE0104333D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
SE0104334D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
GB0229931D0 (en) * 2002-12-21 2003-01-29 Astrazeneca Ab Therapeutic agents
ES2299702T3 (es) 2002-06-20 2008-06-01 Astrazeneca Ab Derivados de acido benzoico orto-sustituidos para el tratamiento de la resistencia a la insulina.
SE0403072D0 (sv) * 2004-12-16 2004-12-16 Astrazeneca Ab Pharmaceutically useful salts of carboxylic acid derivates
WO2007004957A1 (en) * 2005-07-05 2007-01-11 Astrazeneca Ab Novel crystalline form
AR055073A1 (es) * 2005-07-11 2007-08-01 Astrazeneca Ab Agentes terapeuticos
CN103717214A (zh) * 2011-06-06 2014-04-09 阿克比治疗有限公司 用于稳定低氧诱导因子-2α作为治疗癌症的方法的化合物和组合物
NO2686520T3 (es) 2011-06-06 2018-03-17
BR112015031027A2 (pt) 2013-06-13 2017-08-29 Akebia Therapeutics Inc Uso de um composto, método in vitro, composição farmacêutica e forma de dosagem única
MX2021001169A (es) 2013-11-15 2023-02-10 Akebia Therapeutics Inc Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acético, composiciones, y usos de las mismas.
BR112017015852A2 (pt) 2015-01-23 2018-03-27 Akebia Therapeutics Inc forma de cristal, sal hemicálcico, sal hemicálcico di-hidratado, sal monossódico hidratado, sal bissódico monoidratado, sal monossódico anidro e método para preparar o composto 1
IL292262B2 (en) 2015-04-01 2024-02-01 Akebia Therapeutics Inc Formulation of an oral administration form of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid
MX2020011845A (es) 2018-05-09 2021-01-15 Akebia Therapeutics Inc Proceso para preparar acido 2-[[5-(3-clorofenil)-3-hidroxipiridina -2-carbonil]amino]acetico.
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2369871A1 (en) * 1999-04-06 2000-10-12 Takashi Fujita .alpha.-substituted carboxylic acid derivatives
SE0104334D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents

Also Published As

Publication number Publication date
WO2004110984A1 (en) 2004-12-23
BRPI0411525A (pt) 2006-08-01
ZA200510252B (en) 2006-12-27
JP3822900B1 (ja) 2006-09-20
SA04250169A (ar) 2005-12-03
AU2004247610A1 (en) 2004-12-23
NO20055922L (no) 2006-01-06
MXPA05013714A (es) 2006-06-27
UY28375A1 (es) 2005-01-31
IL172167A0 (en) 2009-02-11
KR20060027348A (ko) 2006-03-27
EP1638922A1 (en) 2006-03-29
AU2004247610B2 (en) 2008-04-17
RU2005138590A (ru) 2006-07-27
JP2006527766A (ja) 2006-12-07
GB0314129D0 (en) 2003-07-23
IS8231A (is) 2006-01-13
MY137277A (en) 2009-01-30
AR044801A1 (es) 2005-10-05
UA81807C2 (uk) 2008-02-11
CN1809529A (zh) 2006-07-26
US20060142389A1 (en) 2006-06-29
SA04250169B1 (ar) 2007-08-07
CA2528932A1 (en) 2004-12-23
TW200503677A (en) 2005-02-01

Similar Documents

Publication Publication Date Title
CO5650228A2 (es) Sales farmaceuticamente utiles de derivados de acido carboxilico
RS52716B (en) HYDROBENZAMIDE DERIVATIVES AS HEAT SHOCK PROTEIN INHIBITORS HSP90
ATE540051T1 (de) Age-inhibitoren
RS52214B (en) HDAC INHIBITOR PHARMACEUTICAL FORMULATIONS
CY1115336T1 (el) Συνθεση της βορτεζομιμπης
AR042632A1 (es) Compuestos derivados del acido (2s)-3-(4-{2-[amino]-2-oxoetoxi} fenil)-2-etoxipropanoico como agentes terapeuticos para trastornos en el metabolismo de los lipidos y composiciones farmaceuticas
BR0313178A (pt) Derivados de pirazol e processo para a produção destes
CO5570667A2 (es) Compuestos azabiciclico sustituidos condensados con heteroarilo para el tratamiento de enfermedades
AR049401A1 (es) Aza-biciclononanos
DK1313695T3 (da) Estere af 5-aminolevulinsyre som fotosensibiliserende midler i fotokemoterapi
DOP2002000392A (es) Sales tartrato de 5,8,14 triazatetraciclo [10.3.1.024 0.4.9] hexadeca-2 (11), 3,5,7,9-pentaeno y composiciones farmaceuticas de las mismas
EA200601963A1 (ru) Соли дигидрожасмоновой кислоты и их применение в сельском хозяйстве
AR063449A1 (es) Proceso quimico para derivados de quinazolina, intermediarios
BRPI0812625A2 (pt) processo para preparar um sal de cis-atracúrio
AR057909A1 (es) Proceso para preparar montelukast y compuestos relacionados, que utiliza un compuesto intermediario derivado de un ester sulfonico.
CO6241155A2 (es) [4-(6-fluoro-7-metilamina-2,4-dioxo-1,4-dihidro-2hquinazolina-3-ilo)-fenilo]-5-cloro-tiofeno-2-ilo-sales de sulfonilurea y las formas y metodos relacionados con el mismo
NO20055923L (no) Farmasoytisk anvendbare salter av karboksylsyrderivater
SV2010003770A (es) Composicion y proceso- 356
EA200400129A1 (ru) Способ получения периндоприла, его аналогов и солей с использованием 2,5-диоксооксазолидиновых промежуточных соединений
AR061295A1 (es) Procedimiento para hacer sales de n-hidroxi-3- [4-[ [ [ 2- ( 2-metil-1h-indol-3-il) etil] amino] metil] fenil] -2e-2-propenamida
EA201170057A1 (ru) Способ получения замещенных 2-аминотиазолонов
SE0201661D0 (sv) New salts
EA200800861A1 (ru) Способ получения четвертичных аммониевых солей с кислотой
AR055006A1 (es) Sales farmaceuticamente utiles de derivados de acido carboxilico
AR044267A1 (es) Compuesto intermedio util para la preparacion de pioglitazona

Legal Events

Date Code Title Description
FC Application refused